About this data
Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.
Inclisiran sodium (equivalent to inclisiran) in
- Company
- Duke University
- Mechanism
- Mechanism not yet reported
- Route
- Route not yet reported
- Recruiting trials
- 9 recruiting
Efficacy results: Not yet reported
9 recruiting studies currently listed on ClinicalTrials.gov.
Data source: ClinicalTrials.gov · trial data as of Nov 17, 2026
Find a Clinical Trial Near Me
See recruiting studies for Inclisiran sodium (equivalent to inclisiran) in and check eligibility with the study team.
Trial details
-
Recruiting NCT NCT05682378
Long-term Safety and Tolerability of Inclisiran in Participants With HeFH or HoFH Who Have Completed the Pediatric ORION-16, ORION-13, ORION-20, or ORION-19 Studies
Not yet reported Novartis Pharmaceuticals 195 participants Est. completion 2032-03-28 52 sitesOther conditions: Heterozygous or Homozygous Familial HypercholesterolemiaView official trial listing → -
Recruiting NCT NCT06501443
LATAM LOWERS LDL-C
Not yet reported Novartis Pharmaceuticals 520 participants Est. completion 2026-11-29 11 sites Stand-aloneOther conditions: HypercholesterolaemiaView official trial listing → -
Recruiting NCT NCT06597006
Study to Evaluate Safety, Tolerability and Efficacy of Inclisiran in Children With Homozygous Familial Hypercholesterolemia
Not yet reported Novartis Pharmaceuticals 9 participants Est. completion 2029-04-15 19 sitesOther conditions: Familial Hypercholesterolemia - HomozygousView official trial listing → -
Recruiting NCT NCT06597019
Study to Evaluate Efficacy and Safety of Inclisiran in Children With Heterozygous Familial Hypercholesterolemia
Not yet reported Novartis Pharmaceuticals 60 participants Est. completion 2029-04-15 66 sitesOther conditions: Familial Hypercholesterolemia - HeterozygousView official trial listing → -
Recruiting NCT NCT06865885
LDL-C Optimization Using Inclisiran in Patients in Which Drug-Drug Interactions Limit LDL Lowering
Not yet reported University of California, San Diego 100 participants Est. completion 2028-09-01 1 siteMetabolic syndrome Other conditions: Drug Interactions, Primary Prevention, LDL-Cholersterol Lowering, PolypharmacyView official trial listing → -
Recruiting NCT NCT06909565
Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention
Not yet reported Duke University 6000 participants Est. completion 2029-12 153 sitesOther conditions: Percutaneous Coronary Intervention, Peripheral Endovascular InterventionView official trial listing → -
Recruiting NCT NCT07102628
Evaluation of Efficacy and Safety of Early in Hospital Initiation of Inclisiran Treatment in Patients With Acute Coronary Syndromes
Not yet reported Novartis Pharmaceuticals 300 participants Est. completion 2027-02-11 69 sites Stand-aloneOther conditions: Acute Coronary SyndromeView official trial listing → -
Recruiting NCT NCT07610278
A Study to Evaluate the Pharmacodynamics of a Combination of QCZ484 and Inclisiran in Participants With Hypertension and Concomitant Hypercholesterolemia
Not yet reported Novartis Pharmaceuticals 120 participants Est. completion 2028-02-03 29 sitesOther conditions: HypercholesterolaemiaView official trial listing → -
Recruiting NCT NCT07626281
Assessment of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a New Formulation of Inclisiran Containing Polysorbate 80 Compared to the Currently Marketed Formulation
Not yet reported Novartis Pharmaceuticals 152 participants Est. completion 2026-12-21 6 sitesOther conditions: Inclisiran FormulationView official trial listing → -
Completed NCT NCT03851705
A Study of Inclisiran in Participants With Homozygous Familial Hypercholesterolemia (HoFH)
Not yet reported Novartis Pharmaceuticals 56 participants Est. completion 2021-09-09 13 sitesOther conditions: Homozygous Familial HypercholesterolemiaView official trial listing → -
Completed NCT NCT04652726
Study to Evaluate Efficacy and Safety of Inclisiran in Adolescents With Heterozygous Familial Hypercholesterolemia
Not yet reported Novartis Pharmaceuticals 141 participants Est. completion 2024-11-27 59 sites Stand-aloneOther conditions: Familial Hypercholesterolemia - HeterozygousView official trial listing → -
Completed NCT NCT04659863
Study to Evaluate Efficacy and Safety of Inclisiran in Adolescents With Homozygous Familial Hypercholesterolemia
Not yet reported Novartis Pharmaceuticals 13 participants Est. completion 2024-11-18 11 sites Stand-aloneOther conditions: Familial Hypercholesterolemia - HomozygousView official trial listing → -
Completed NCT NCT04666298
Study of Efficacy and Safety of Inclisiran in Japanese Participants With High Cardiovascular Risk and Elevated LDL-C
Not yet reported Novartis Pharmaceuticals 312 participants Est. completion 2022-10-19 42 sitesOther conditions: Hypercholesterolemia, Heterozygous Familial HypercholesterolemiaView official trial listing → -
Active, not recruiting NCT NCT04765657
Study of Efficacy and Safety of Inclisiran in Asian Participants With Atherosclerotic Cardiovascular Disease (ASCVD) or ASCVD High Risk and Elevated Low Density Lipoprotein Cholesterol (LDL-C)
Not yet reported Novartis Pharmaceuticals 345 participants Est. completion 2026-12-28 45 sitesOther conditions: HypercholesterolemiaView official trial listing → -
Completed NCT NCT04774003
Study of Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inclisiran in Chinese Participants With Elevated Serum LDL-C
Not yet reported Novartis Pharmaceuticals 40 participants Est. completion 2021-10-18 3 sitesOther conditions: HyperlipidemiaView official trial listing → -
Completed NCT NCT04873934
Management of LDL-cholesterol With Inclisiran + Usual Care Compared to Usual Care Alone in Participants With a Recent Acute Coronary Syndrome
Not yet reported Novartis Pharmaceuticals 400 participants Est. completion 2024-08-07 88 sitesOther conditions: Acute Coronary SyndromeView official trial listing → -
Active, not recruiting NCT NCT05030428
Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease
Not yet reported Novartis Pharmaceuticals 17004 participants Est. completion 2027-05-10 989 sitesCardiovascular diseaseView official trial listing → -
Completed NCT NCT05192941
Study of Efficacy, Safety, Tolerability and Quality of Life of Inclisiran (KJX839) vs Placebo, on Top of Ongoing Individually Optimized Lipid-lowering Therapy, in Participants With Hypercholesterolemia
Not yet reported Novartis Pharmaceuticals 1770 participants Est. completion 2025-03-19 136 sitesOther conditions: HypercholesterolemiaView official trial listing → -
Active, not recruiting NCT NCT05360446
Coronary Computed Tomography Study to Assess the Effect of Inclisiran in Addition to Maximally Tolerated Statin Therapy on Atherosclerotic Plaque Progression in Participants With a Diagnosis of Non-obstructive Coronary Artery Disease Without Previous Cardiovascular Events
Not yet reported Novartis Pharmaceuticals 610 participants Est. completion 2026-10-27 89 sitesCardiovascular diseaseView official trial listing → -
Active, not recruiting NCT NCT05739383
A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.
Not yet reported Novartis Pharmaceuticals 14012 participants Est. completion 2029-04-16 983 sites Stand-aloneCardiovascular diseaseView official trial listing → -
Completed NCT NCT05763875
Efficacy and Safety of Inclisiran as Monotherapy in Patients With Primary Hypercholesterolemia Not Receiving Lipid-lowering Therapy.
Not yet reported Novartis Pharmaceuticals 350 participants Est. completion 2024-06-20 42 sitesOther conditions: HypercholesterolemiaView official trial listing → -
Completed NCT NCT05888103
Efficacy and Safety of Inclisiran as Monotherapy in Chinese Adults With Low or Moderate ASCVD Risk and Elevated Low-density Lipoprotein Cholesterol.
Not yet reported Novartis Pharmaceuticals 207 participants Est. completion 2024-10-24 28 sitesOther conditions: Primary Hypercholesterolemia or Mixed DyslipidemiaView official trial listing → -
Completed NCT NCT05974345
In Silico Study Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Patients With Established Cardiovascular Disease
Novartis Pharmaceuticals 204691 participants Est. completion 2023-12-15 1 siteCardiovascular diseaseView official trial listing → -
Completed NCT NCT06386419
A Clinical Study to Evaluate the Safety and Effectiveness of Inclisiran Sodium in Indian Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia
Not yet reported Novartis Pharmaceuticals 65 participants Est. completion 2026-01-13 9 sitesOther conditions: Primary Hypercholesterolemia, Mixed DyslipidemiaView official trial listing → -
Active, not recruiting NCT NCT06958315
Inclisiran (Leqvio®) in Patients With Atherosclerotic Vascular Disease and/or Heterozygous Familial Hypercholesterolemia Treated in Spain: the INSPIRE Study
Novartis Pharmaceuticals 219 participants Est. completion 2027-05-01 20 sitesOther conditions: Atherosclerotic Vascular Disease, Heterozygous Familial HypercholesterolemiaView official trial listing → -
Not yet recruiting NCT NCT07684469
Comparative Assessment of Inclisiran on Top of Standard of Care Versus Standard of Care Alone for LDL-C Evaluation in Acute Coronary Syndrome Patients in Saudi Arabia
Not yet reported Novartis Pharmaceuticals 300 participants Est. completion 2029-02-28Other conditions: Acute Coronary SyndromeView official trial listing →
Efficacy history
Not yet reported.
Safety
Not yet reported.
Sources
Also known as: Inclisiran sodium (equivalent to inclisiran) in, Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL, KJX839
Related On The Pen coverage
No related coverage yet.
This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.
